Slide 1: Stockholder Presentation 2026 Annual Meeting
Stockholder Q2Presentation 2025 Investor Call August 6, 2025 2026 Annual Meeting
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Update on Key Topics
Business & Strategy Board of Management Supervisory Board BoM Compensation Update on Key Topics Focused execution of our strategy is driving strong progress on items important to our shareholders Bayer has made significant progress on our key priorities, and expects to finish 2026 in a much stronger
Slide 4: 2024-26 Strategic Plan
Business & Strategy Board of Management Supervisory Board BoM Compensation 2024-26 Strategic Plan Bayer has set clear priorities to deliver for our shareholders and we are making strong progress on our three-year plan 2024 2025 2026 Ongoing Initiated steps to address Advanced on our key Improved lon
Slide 5: Progress on Bayer's Five Key Priorities
Business & Strategy Board of Management Supervisory Board BoM Compensation Progress on Bayer’s Five Key Priorities Bayer is on track with the three-year plan, advancing our priorities to improve performance and strengthen our positioning Crop Science Executing against Crop Science’s five-year framew
Slide 6: Updates on Managing Litigation Risk
Business & Strategy Board of Management Supervisory Board BoM Compensation Updates on Managing Litigation Risk Multi-pronged approach to protect our liquidity, resolve claims at scale, and contain our exposure Workstreams Recent Updates Litigation // Monsanto has reached a proposed nationwide glypho
Slide 7: Board of Management Update
Business & Strategy Board of Management Supervisory Board BoM Compensation Board of Management Update Appointment of Judith Hartmann as CFO supports our continued advancement of key strategic and financial priorities Bill Anderson Heike Prinz CEO of Bayer Chief Talent Officer Judith Hartmann Joined
Slide 8: Supervisory Board Composition
Business & Strategy Board of Management Supervisory Board BoM Compensation Supervisory Board Composition Two proposed nominees support continued refreshment and bring valuable skills and expertise to the Supervisory Board Prof. Dr. Norbert Winkeljohann Horst Baier New nominees at the 2026 Annual Sto
Slide 9: Stockholder Representatives' Skills are Aligned to Our Strategy
Business & Strategy Board of Management Supervisory Board BoM Compensation Stockholder Representatives’ Skills are Aligned to Our Strategy Following new additions, Supervisory Board is well-positioned to oversee our turnaround plan and next strategic phase Winkel- Baier Cousin Mathisen Schechter Sim
Slide 10: 2025 Board of Management Compensation
Business & Strategy Board of Management Supervisory Board BoM Compensation 2025 Board of Management Compensation Extensive shareholder engagement informed 2025 implementation and enhanced Compensation Report disclosure Base Salary Fixed compensation Attainment: 2025 Performance Period Target Attaine
Slide 11: We Request Your Support at the 2026 Annual Stockholders' Meeting
Business & Strategy Board of Management Supervisory Board BoM Compensation We Request Your Support at the 2026 Annual Stockholders’ Meeting Select Agenda Items Reason to Support 2026 reflects the third year of the previously announced reduced dividend, with Bayer focused on 1 Distribution of the Pro